{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:38:21Z","timestamp":1793921901922,"version":"4.8.0"},"reference-count":62,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Pemafibrate (PEM) is a novel lipid-lowering drug classified as a selective peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) modulator whose binding efficiency to PPAR\u03b1 is superior to that of fibrates. This agent is also useful for non-alcoholic fatty liver disease and primary biliary cholangitis with dyslipidemia. The dose of PEM used in some previous mouse experiments is often much higher than the clinical dose in humans; however, the precise mechanism of reduced serum triglyceride (TG) for the clinical dose of PEM has not been fully evaluated. To address this issue, PEM at a clinically relevant dose (0.1 mg\/kg\/day) or relatively high dose (0.3 mg\/kg\/day) was administered to male C57BL\/6J mice for 14 days. Clinical dose PEM sufficiently lowered circulating TG levels without apparent hepatotoxicity in mice, likely due to hepatic PPAR\u03b1 stimulation and the enhancement of fatty acid uptake and \u03b2-oxidation. Interestingly, PPAR\u03b1 was activated only in the liver by PEM and not in other tissues. The clinical dose of PEM also increased serum\/hepatic fibroblast growth factor 21 (FGF21) without enhancing hepatic lipid peroxide 4-hydroxynonenal or inflammatory signaling. In conclusion, a clinically relevant dose of PEM in mice efficiently and safely reduced serum TG and increased FGF21 targeting hepatic PPAR\u03b1. These findings may help explain the multiple beneficial effects of PEM observed in the clinical setting.<\/jats:p>","DOI":"10.3390\/biomedicines10071667","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T21:57:53Z","timestamp":1657576673000},"page":"1667","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor \u03b1 Modulator (SPPARM\u03b1), Lowers Serum Triglyceride Levels by Targeting Hepatic PPAR\u03b1 in Mice"],"prefix":"10.3390","volume":"10","author":[{"given":"Zhe","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Diao","sequence":"additional","affiliation":[{"name":"Department of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuguang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takero","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3212-3836","authenticated-orcid":false,"given":"Naoki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan"},{"name":"International Relations Office, Shinshu University School of Medicine, Matsumoto 390-8621, Japan"},{"name":"Research Center for Social Systems, Shinshu University, Matsumoto 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbalip.2012.02.005","article-title":"Triglyceride: One molecule at the center of health and disease","volume":"1821","author":"Goldberg","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1074\/jbc.M114.605980","article-title":"Adipocyte-specific Disruption of Fat-specific Protein 27 Causes Hepatosteatosis and Insulin Resistance in High-fat Diet-fed Mice","volume":"290","author":"Tanaka","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(96)07493-4","article-title":"Mortality by cause for eight regions of the world: Global Burden of Disease Study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1475-2840-5-20","article-title":"Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: Therapeutic options beyond statins","volume":"5","author":"Tenenbaum","year":"2006","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1016\/S0140-6736(14)61744-X","article-title":"Patchy progress on obesity prevention: Emerging examples, entrenched barriers, and new thinking","volume":"385","author":"Roberto","year":"2015","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1542\/pir.2019-0053","article-title":"Hyperlipidemia","volume":"41","author":"Stewart","year":"2020","journal-title":"Pediatr. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Botta, M., Audano, M., Sahebkar, A., Sirtori, C.R., Mitro, N., and Ruscica, M. (2018). PPAR Agonists and Metabolic Syndrome: An Established Role?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041197"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-017-0818-x","article-title":"Pemafibrate: First Global Approval","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1016\/j.bmc.2014.05.008","article-title":"Triglyceride-lowering agents","volume":"22","author":"Salakhutdinov","year":"2014","journal-title":"Bioorganic Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/mol.108.052928","article-title":"Bezafibrate at Clinically Relevant Doses Decreases Serum\/Liver Triglycerides via Down-Regulation of Sterol Regulatory Element-Binding Protein-1c in Mice: A Novel Peroxisome Proliferator-Activated Receptor \u03b1-Independent Mechanism","volume":"75","author":"Nakajima","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sasaki, Y., Raza-Iqbal, S., Tanaka, T., Murakami, K., Anai, M., Osawa, T., Matsumura, Y., Sakai, J., and Kodama, T. (2019). Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor \u03b1 Modulator (SPPARM\u03b1) Pemafibrate. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225682"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/postgradmedj-2011-130594","article-title":"Fibrates and estimated glomerular filtration rate: Observations from an outpatient clinic setting and clinical implications: Figure 1","volume":"88","author":"Abbas","year":"2012","journal-title":"Postgrad. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety Considerations with Fibrate Therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrendo.2009.151","article-title":"Myopathy with statin\u2013fibrate combination therapy: Clinical considerations","volume":"5","author":"Jacobson","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/hepr.13770","article-title":"Pemafibrate for primary biliary cholangitis with dyslipidemia: A proposal of a new treatment from Japan","volume":"52","author":"Tanaka","year":"2022","journal-title":"Hepatol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a New Selective PPAR\u03b1 Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.atherosclerosissup.2018.04.475","article-title":"Pemafibrate Has High Bioavailability and is Principally Excreted via the Liver","volume":"32","author":"Hounslow","year":"2018","journal-title":"Atheroscler. Suppl."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., and Ishibashi, S. (2019). Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-\u03b1 Modulator (SPPARM\u03b1), in Dyslipidemic Patients with Renal Impairment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030706"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.dmpk.2020.03.005","article-title":"Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1","volume":"35","author":"Ogawa","year":"2020","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.5551\/jat.28720","article-title":"Transcriptome Analysis of K-877 (a Novel Selective PPAR\u03b1 Modulator (SPPARM\u03b1))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver","volume":"22","author":"Tanaka","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","article-title":"The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis","volume":"249","author":"Hennuyer","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_25","first-page":"1596","article-title":"Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet","volume":"1841","author":"Tanaka","year":"2014","journal-title":"Biochim. Biophys. Acta BBA Mol. Cell Biol. Lipids"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/0003-2697(78)90046-5","article-title":"Lipid extraction of tissues with a low-toxicity solvent","volume":"90","author":"Hara","year":"1978","journal-title":"Anal. Biochem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0009-9120(93)90015-X","article-title":"Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts","volume":"26","author":"Carr","year":"1993","journal-title":"Clin. Biochem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.bbadis.2015.02.012","article-title":"Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet","volume":"1852","author":"Tanaka","year":"2015","journal-title":"Biochim. Biophys. Acta BBA Mol. Basis Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000508308","article-title":"Dietary Restriction Suppresses Steatosis-Associated Hepatic Tumorigenesis in Hepatitis C Virus Core Gene Transgenic Mice","volume":"9","author":"Jia","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1074\/jbc.273.10.5678","article-title":"Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha)","volume":"273","author":"Aoyama","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-981-15-6082-8_4","article-title":"Microsomal Triglyceride Transfer Protein: From Lipid Metabolism to Metabolic Diseases","volume":"1276","author":"Iqbal","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3892\/etm.2011.328","article-title":"Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease","volume":"2","author":"Higuchi","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1586\/egh.11.22","article-title":"Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease","volume":"5","author":"Pereira","year":"2011","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kawanishi, H., Ohashi, K., Ogawa, H., Otaka, N., Takikawa, T., Fang, L., Ozaki, Y., Takefuji, M., Murohara, T., and Ouchi, N. (2020). A novel selective PPAR\u03b1 modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0235362"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12933-020-01132-2","article-title":"Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl\/salt-sensitive rats fed a high-salt and high-fat diet","volume":"19","author":"Yoshida","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e05431","DOI":"10.1016\/j.heliyon.2020.e05431","article-title":"Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet","volume":"6","author":"Horikawa","year":"2020","journal-title":"Heliyon"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.5551\/jat.61101","article-title":"Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor \u03b1 Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice","volume":"28","author":"Suto","year":"2021","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11883-020-00897-x","article-title":"Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARM\u03b1) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?","volume":"23","author":"Fruchart","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5551\/jat.39693","article-title":"A Novel Selective PPAR\u03b1 Modulator (SPPARM\u03b1), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice","volume":"25","author":"Sairyo","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s12328-021-01386-7","article-title":"Pemafibrate, a novel selective PPAR\u03b1 modulator, attenuates tamoxifen-induced fatty liver disease","volume":"14","author":"Tanaka","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5551\/jat.48918","article-title":"Clinical Applications of a Novel Selective PPAR\u03b1 Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases","volume":"26","author":"Yamashita","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.tem.2019.05.007","article-title":"Going Back to the Biology of FGF21: New Insights","volume":"30","author":"Lewis","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1530\/EC-20-0152","article-title":"FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation","volume":"9","author":"Keinicke","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1074\/jbc.M112.341248","article-title":"Fibroblast Growth Factor-21 (FGF21) Regulates Low-density Lipoprotein Receptor (LDLR) Levels in Cells via the E3-ubiquitin Ligase Mylip\/Idol and the Canopy2 (Cnpy2)\/Mylip-interacting Saposin-like Protein (Msap)","volume":"287","author":"Do","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.cmet.2018.04.002","article-title":"FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2\/Angiotensin-(1\u20137) Axis in Mice","volume":"27","author":"Pan","year":"2018","journal-title":"Cell Metab."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Tomita, Y., Lee, D., Miwa, Y., Jiang, X., Ohta, M., Tsubota, K., and Kurihara, T. (2020). Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176243"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/JOE-15-0289","article-title":"Effects of fibroblast growth factor 21 on the heart","volume":"227","author":"Tanajak","year":"2015","journal-title":"J. Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cvr\/cvu263","article-title":"Fibroblast growth factor 21 protects the heart from oxidative stress","volume":"106","author":"Planavila","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1097\/CM9.0000000000001890","article-title":"The role of FGF21 in the pathogenesis of cardiovascular disease","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin. Med. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The Metabolic State of Diabetic Monkeys Is Regulated by Fibroblast Growth Factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"bqab092","DOI":"10.1210\/endocr\/bqab092","article-title":"FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction","volume":"162","author":"Diener","year":"2021","journal-title":"Endocrinology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1007\/s00125-017-4389-x","article-title":"FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes","volume":"60","author":"Laeger","year":"2017","journal-title":"Diabetologia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"42477","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Araki, M., Nakagawa, Y., Oishi, A., Han, S.-I., Wang, Y., Kumagai, K., Ohno, H., Mizunoe, Y., Iwasaki, H., and Sekiya, M. (2018). The Peroxisome Proliferator-Activated Receptor \u03b1 (PPAR\u03b1) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19072148"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pharmthera.2017.05.011","article-title":"Targeting nuclear receptors for the treatment of fatty liver disease","volume":"179","author":"Tanaka","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wang, Y., Nakajima, T., Gonzalez, F.J., and Tanaka, N. (2020). PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062061"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/toxsci\/kfab068","article-title":"Species Differences between Mouse and Human PPAR\u03b1 in Modulating the Hepatocarcinogenic Effects of Perinatal Exposure to a High-Affinity Human PPAR\u03b1 Agonist in Mice","volume":"183","author":"Koga","year":"2021","journal-title":"Toxicol. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lee, D., Tomita, Y., Jeong, H., Miwa, Y., Tsubota, K., Negishi, K., and Kurihara, T. (2021). Pemafibrate Prevents Retinal Dysfunction in a Mouse Model of Unilateral Common Carotid Artery Occlusion. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179408"},{"key":"ref_62","first-page":"659","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Nihal","year":"2008","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1667\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:48:09Z","timestamp":1760140089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071667"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071667","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]}}}